The continuously growing NK-92 cell line is highly cytotoxic against a broad spectrum
of tumor targets and has completed phase I clinical trials in humans. To further improve
the anticancer activity towards ErbB2 expressing cancer cells NK-92 cells from an
FDA-licensed master cell stock (MCS) were transduced under GMP-compliant conditions
with an ErbB2-specific humanized CAR construct by lentiviral gene transfer.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
76
Identification
Copyright
© 2014 Published by Elsevier Inc.
